ArticleFrontiers in medicine2025
Spontaneous inferior epigastric artery hemorrhage in a COVID-19 patient with membranous nephropathy on anticoagulant therapy: a Case Report.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The management of Coronavirus disease 2019 (COVID-19) is complicated by coagulopathies that increase both thrombotic and hemorrhagic risks, particularly in patients with comorbidities such as membranous nephropathy (MN) who require anticoagulation. Spontaneous inferior epigastric artery (IEA) hemorrhage is a rare but life-threatening complication in this setting. Case presentation: A 63-years-old woman with M-type phospholipase A2 receptor (PLA2R)-positive MN was admitted for COVID-19 pneumonia and acute respiratory distress syndrome (ARDS). Despite prophylactic anticoagulation with dalteparin, her respiratory status deteriorated, requiring intensive care. On day 24, she developed sudden hemorrhagic shock due to a rectus sheath hematoma from spontaneous IEA rupture, confirmed by imaging and surgical exploration. The hemorrhage was managed with ligation, transfusion, and discontinuation of anticoagulation. Her recovery was marked by resolution of pulmonary and hemorrhagic complications by day 46, and 3-months follow-up showed no recurrence of bleeding or thrombotic events. Conclusion: This case highlights the critical balance between thromboprophylaxis and bleeding risk in COVID-19 patients with MN. It underscores the need for individualized anticoagulation strategies, pharmacodynamic monitoring, and multidisciplinary decision-making to mitigate risks in this high-risk population. The interplay of COVID-19-induced coagulopathy, renal impairment, and immunosuppressive therapy amplifies both thrombotic and hemorrhagic tendencies, necessitating extreme vigilance in clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.